Previous 10 | Next 10 |
home / stock / lly / lly articles
Thursday, Evernorth Health Services, a subsidiary of Cigna Group (NYSE:CI) introduced a financial guarantee within its EncircleRx pr...
In a move outlined in his upcoming State of the Union address, President Joe Biden is pushing for an increase in the number of prescripti...
Thursday, Novo Nordisk A/S (NYSE:NVO) is holding its Capital Markets Day. Its executive management and other members of senior management...
CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if underva...
BofA Securities says Eli Lilly and Company (NYSE:LLY) remains a top choice in Biopharma analysis, boasting a remarkable year-to-date...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 10 years by 18.82% on an annualized basis producing an average annual return ...
The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be res...
Viking Therapeutics Inc (NASDAQ:VKTX) recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 d...
Eli Lilly And Co’s (NYSE:LLY) CEO, David Ricks, shared the pharmaceutical giant’s plans to introduce its obesity drug, tirzepatide...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...